Delcath Systems Inc (DCTH)

0.09
0.00 1.10
NASDAQ : Health Care
Prev Close 0.09
Open 0.09
Day Low/High 0.08 / 0.10
52 Wk Low/High 3.35 / 10.88
Volume 9.74M
Avg Volume 6.93M
Exchange NASDAQ
Shares Outstanding 70.60M
Market Cap 6.35M
EPS -14.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential Of Delcath Investigational PHP Therapy

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential Of Delcath Investigational PHP Therapy

Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders

Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort

Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort

Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICC

Delcath Issues Letter To Stockholders

Delcath Issues Letter To Stockholders

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Prices Underwritten Public Offering Of Common Stock And Warrants

Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Data Supporting CHEMOSAT Presented At The Cardiovascular And Interventional Radiology Society Of Europe Conference

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective Analysis

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Delcath European Patient Education Website Receives Prestigious Digital Health Award

Againsttheodds.eu Recognized for High Quality Consumer Health Content

Delcath Announces First CHEMOSAT® Procedures In Turkey

Delcath Announces First CHEMOSAT® Procedures In Turkey

Growing Adoption of CHEMOSAT Permits Expansion Outside of European Union

Delcath Announces Engagement Of Lars E. Birgerson, M.D., Ph. D As Global Medical Consultant

Delcath Announces Engagement Of Lars E. Birgerson, M.D., Ph. D As Global Medical Consultant

Distinguished Physician and Pharmaceutical Industry Executive to Serve as Senior Advisor for Clinical Development